The level of laboratory service will vary between different centres. Specialist virology laboratories will undertake a full range of influenza virus testing, including the rapid detection, culture and typing of isolates for potential use in vaccines, and the detection of antiviral drug resistance. Other laboratories may undertake a more limited range of services depending on their location (for example, in rural areas), their population (for example, in public or private hospitals) and access to specialised laboratories. The identification of the earliest cases of a novel influenza strain will require co-operation and communication between public health practitioners, treating clinicians and both public and private laboratories. These issues are discussed in the technical annexes of the Australian Health Management Plan for Pandemic Influenza and in the World Health Organization (WHO) and Centers for Disease Control (USA) pandemic plans.
1-3 laBORatORy dIagNOSIS Of INflueNza

Collection of samples
The key to successful laboratory diagnosis of influenza is the collection of the appropriate respiratory tract samples. This poses the challenge of ensuring that enough people are trained in safe and reliable specimen collection techniques prior to a pandemic. A swab from each nostril and a swab from the throat are recommended for adults (the specimens are combined in the laboratory, hence the name 'combined' nose and throat swab); nasopharyngeal aspirates may be collected in children less than three years of age. In severely ill hospitalised patients, lower respiratory tract samples such as bronchoalveolar lavage fluid are especially useful. Samples should be collected in the first three to four days following the onset of symptoms (as this is when the viral load is highest), and transported to the laboratory as quickly as possible. Early experience of human infection with influenza A/H5N1 infections suggests that the virus is more readily detectable in lower respiratory tract samples, although blood, faeces and cerebrospinal fluid may also contain virus. Nucleic acid testing (NAT) is highly sensitive and specific for the detection of influenza and other respiratory virus genomes.
4,5
Diagnostic methods
7 Pandemic strain-specific NAT (for example, as developed for influenza A/H5N1) will be the diagnostic test of choice in a pandemic.
1-3 It can be used on a range of clinical specimens and can be performed reasonably quickly, depending on the laboratory's testing platform. NAT can be directed against highly conserved regions of the influenza Virus antigen and nucleic acid testing methods have a quicker turnaround time than virus isolation, and are performed in more laboratories. Influenza antigens can be detected by immunofluorescence, using monoclonal antibodies that distinguish between influenza A or B, or between H3 or H1 subtypes. 7 Other rapid antigen detection systems include enzyme immunoassays and 'point of care' tests. The point of care tests, generally based on immunochromatographic platforms using monoclonal antibodies specific to conserved regions of influenza A or B, are simple to perform and can be used in laboratories (especially if virology resources are limited), or elsewhere, such as in doctor's surgeries, accident and emergency departments or influenza clinics. In general terms, their specificity is good (making them useful in investigating outbreaks or in surveillance) and their rapidity makes them useful for commencing antiviral therapy quickly. 12 The sensitivity and specificity of the rapid antigen detection tests against influenza A/H5N1 strains are still uncertain.
Influenza-specific antibodies can be detected by various methods such as complement fixation, immunofluorescence, enzyme immunoassays, haemagglutinin inhibition and neutralisation, tests that are technically complex and difficult to perform in large numbers. Serological testing usually requires both acute and convalescent (collected four to six weeks after disease onset) samples, and has a role in detecting atypical infections and making retrospective diagnoses, and in epidemiological studies.
Reliability of testing
A challenge for Australian laboratories is ensuring that their testing is reliable for viruses not yet circulating in Australia, such as the current influenza A/H5N1 strains. Genetic variation in the viruses over time may particularly affect the reliability of NAT 9 , and the lack of clinical samples in Australia from influenza A/H5N1-infected individuals makes local assessment of the various methods uncertain. Pandemic strain-specific primers will be required (eg H5). Quantitation (of viral load) will not routinely be available.
May also be applied to non-respiratory tract samples, eg serum, faeces, cerebrospinal fluid.
Virus isolation Vaccine strain determination and genotyping
Will be limited to laboratories with Physical Containment level 3 facilities and virus culture expertise.
Other laboratory tests used in a pandemic
Nucleic acid testing To detect all influenza A H subtypes, including seasonal human influenza Uses nucleoprotein or matrix primers, or primers specific for influenza A/H3N2, A/H1N1 and influenza B. It picks all H types, but doesn't separate H5 from the others.
To detect other respiratory pathogens
Primers can be multiplexed to detect more than one virus.
Immunofluorescence
To detect all influenza A (or human H3 and H1) or influenza B Developing reliable tests for the pandemic strain, including quality assurance, laboratory training and use of specialised confirmatory tests (such as virus isolation), is an expensive process and not covered by current pathology funding mechanisms. Recent 'urgent research' funding through the National Health and Medical Research Council has allowed the assessment and quality assurance of various influenza A/H5N1-specific tests.
dIagNOStIC StRategIeS duRINg a PaNdemIC
A major challenge will be determining diagnostic strategies during the different pandemic phases. These will vary between laboratories according to their virology expertise, capacity, patient populations, and availability of various assays, and the stage of the pandemic. Table 2 lists the possible diagnostic testing approaches during a pandemic.
In the very early phases, where containment is paramount, testing will have to be rapid to identify the first arrival(s) and clusters of disease. Highly sensitive tests such as pandemic strain-specific nucleic acid testing using polymerase chain reaction or related technologies are required. However, should the pandemic be widespread in Australia (phases 6a-d, as defined in the Australian Health Management Plan for Pandemic Influenza 1 ), testing strategies may change. One could argue that at this phase in the pandemic, clinical identification will suffice (as is often the case during the usual seasonal influenza outbreaks) and laboratory testing should be limited to patients requiring hospital admission or for particular outbreaks. Rapid or point of care tests, although less sensitive and less specific for the pandemic strain, may be a useful addition in these stages of the pandemic. Antiviral resistance testing, although yet not routinely available in Australia, will be important if antiviral drugs are used extensively.
1,8 laBORatORy WORkPlaCe ISSueS duRINg a PaNdemIC
A particular challenge for laboratories will be coping with the surge of work during the early phases of the pandemic when the implications of 'positive' results are particularly high, and at a time when normal laboratory services will continue. There will be heightened community (and media) anxiety about influenza, and healthcare workers will have to deal with their own concerns about the pandemic. Issues of absenteeism, access to antiviral prophylaxis, and maintaining non-pandemic related laboratory medicine services will need consideration. Laboratory workers are generally well trained in biosafety and related infection control issues (current guidelines provide advice about laboratory precautions 1-3 ), so there should be no additional work-related safety issues specific to managing specimens during a pandemic. Interactions between the public and private laboratories will need to be strengthened, given that influenza often presents to general practitioners.
CONCluSION
There are a range of laboratory tests that detect seasonal influenza (influenza A/H3N2 and A/H1N1, influenza B), with their availability dependent on local laboratory practices and resources. Should a pandemic strain emerge, for example from the current avian influenza A/H5N1 virus, then pandemic-virus-specific tests will be needed. In this situation, specific nucleic acid testing will be the test of choice, with virus isolation also needed for evaluation of vaccine strains and genetic drift. The success of laboratory diagnosis is very much dependent on good quality specimen collection and early communication with the laboratory.
